Located in South Downtown Chicago, connected to the McCormick Place and the main AHA Sessions!
AGENDA
Opening Remarks and Introductions
Cardiovascular Protection in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes (T2D)
CKD as a cardiovascular risk factor
The importance of identifying CKD to improve CVD risk assessment: new implications and perspectives
Novel Nonsteroidal MRAs in Patients with CKD and T2DM
Rationale and mechanisms of action
Cardiorenal risk reduction: evidence from clinical trials
The Role of Nonsteroidal MRAs in Cardiovascular Care
How nonsteroidal MRAs fit in with other cardioprotective therapies
Guideline updates & patient selection
Patient Case, Panel Discussions and Future Directions
Q & A and Conclusions
Key Reasons to Attend
Learn more about the importance of chronic kidney disease and type 2 diabetes as major drivers of cardiovascular morbidity and mortality
Be up-to-date about the data with novel nonsteroidal MRAs in cardiorenal risk reduction, and how this new approach fits in with existing treatment options
Hear from top-experts on how to apply this evidence to reduce the risk of cardiovascular and renal adverse events in patients with chronic kidney disease and type 2 diabetes
Pre-Register below to be added to our VIP attendance list and be given priority to join this event. Registration to this event is complimentary, however you must be a registered attendee of the 2022 Scientific Sessions.
This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.
This satellite symposium is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
This event is not part of the official Scientific Sessions as planned by the AHA Committee on Scientific Sessions Programming.
Accreditation
ACTIVITY TITLE Expert Perspectives and Discussions: What You Need to Know About Optimizing Cardiorenal Outcomes with Novel Non-Steroidal MRAs
ACTIVITY DATE Sunday, November 6, 2022
7:30 p.m. – 9:00 p.m.
Marriott Marquis
2121 South Prairie Avenue,
Chicago IL, 60616
TARGET AUDIENCE US-based healthcare professionals, including cardiologists, primary care physicians, endocrinologists, lipidologists as well as nurses, nurse practitioners, and pharmacists.
EDUCATIONAL GRANT SUPPORT This activity is supported by educational grant from Bayer HealthCare Pharmaceuticals Inc.
EDUCATIONAL OBJECTIVES After completing this activity, the participant should be better able to:
Recognize the burden of comorbid CKD and T2DM as a major driver of cardiovascular and renal morbidity and mortality.
Identify T2DM patients at risk for kidney disease or kidney disease progression based on recommended diagnostic practices.
Summarize the efficacy, safety, and mechanisms of action of nonsteroidal MRAs and other emerging treatment options for DKD.
Select tailored treatment regimens that reduce the risk of cardiorenal adverse events in T2DM patients with CKD.
JOINT PROVIDERSHIP STATEMENT This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACIST ACCREDITATION STATEMENT
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Credit Designation
Global Education Group designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number (UAN): TBD.
This is a knowledge-based activity.
GLOBAL CONTACT INFORMATION For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
HOW TO REQUEST CE CREDIT More information on this to come.
DISCLOSURES Information on planner and faculty disclosure will be made available soon.
DISCLOSURE OF UNLABELED USE This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
